Skip to main content
SpringerLink
Log in

Botulinum Toxin Treatment in Urological Disorders

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

  • 408 Accesses

Abstract

Botulinum toxin (BoNT) injection has been widely accepted by the urology and urogynecology medical communities as a safe and effective treatment for refractory urinary incontinence based on two decades of published literature. Currently, there are two approved genitourinary indications for botulinum toxin within the United States. OnabotulinumtoxinA (onaBoNTA) 200 units for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant to an anticholinergic medication was approved by the FDA in 2011. In addition, onaBoNTA 100 units for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant to an anticholinergic medication was approved by the FDA in 2013. We will update the reader on the latest application of botulinum toxin for urologic indications with a focus on bladder injections as well as on potential uses of BoNT in the prostate and pelvic floor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women. Obstet Gynecol. 2006;108:915–23.

    Article  Google Scholar 

  2. Adelowo A, Hacker MR, Shapiro A, et al. Botulinum Toxin Type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013;19:288–92.

    Article  Google Scholar 

  3. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodynam. 2002;21:167–78.

    Article  Google Scholar 

  4. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316:1366–74.

    Article  CAS  Google Scholar 

  5. Bayrak O, Sadioglu E, Sen H, Dogan K, Erturhan S, Seckiner I. Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity. Neurourol Urodyn. 2017;36(8):2078–82.

    Article  CAS  Google Scholar 

  6. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil. 2006;85:536–45.

    Article  Google Scholar 

  7. Chancellor MB, Smith CP: Botulinum toxin in urology, 2011, Springers, http://www.springer.com/medicine/urology/book/978-3-642-03579-1?changeHeader.

  8. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62.

    Article  CAS  Google Scholar 

  9. Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 u significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.

    Article  CAS  Google Scholar 

  10. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006;98(5):1033–7.

    Article  CAS  Google Scholar 

  11. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742–50.

    Article  CAS  Google Scholar 

  12. Denys P, Del Popolo G, Amarenco G, et al. Dysport Study Group. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2016; https://doi.org/10.1002/nau.22954.

  13. de Seze M, Petit H, Gallien P, et al. Botulinum A toxin and detrusor-sphincter-dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42:56–62.

    Article  Google Scholar 

  14. Dykstra D, Sidi A, Scott A, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–22.

    Article  CAS  Google Scholar 

  15. Gallien P, Reymann J-M, Amarenco G, et al. Placebo controlled, randomized, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76:1670–6.

    Article  CAS  Google Scholar 

  16. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104:922–5.

    Article  CAS  Google Scholar 

  17. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9.

    Article  CAS  Google Scholar 

  18. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–80.

    Article  Google Scholar 

  19. Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–53.

    Article  Google Scholar 

  20. Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, Rogers RG, Ellington D, Ferrando CA, Chermansky CJ, Mazloomdoost D, Thomas S, NICHD Pelvic Floor Disorders Network. Cost effectiveness of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial. J Urol. 2019;18:101097JU0000000000000656. https://doi.org/10.1097/JU.0000000000000656. [Epub ahead of print]

    Article  Google Scholar 

  21. Hascoet J, Peyronnet B, Forin V, Baron M, Capon G, Prudhomme T, Allenet C, Tournier S, Maurin C, Cornu JN, Bouali O, Peycelon M, Arnaud A, Renaux-Petel M, Liard A, Karsenty G, Manunta A, Game X. Intradetrusor injections of botulinum toxin type A in children with spina bifida: a multicenter study. Urology. 2018;116:161–7.

    Article  Google Scholar 

  22. Kennelly M, Dmochowski R, Ethans K, et al. Efficacy and safety of OnabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodynam. 2015; https://doi.org/10.1002/nau.22934.

  23. Kuo HC. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology. 2007;69:57–61; discussion 61–52

    Article  Google Scholar 

  24. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657–61.

    Article  CAS  Google Scholar 

  25. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia; results of a randomized, placebo-controlled study. Urology. 2003;62:259–64.

    Article  Google Scholar 

  26. McVary KT, Roehrborn CG, Chartier-Kastler E, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2014;192:150–6.

    Article  CAS  Google Scholar 

  27. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–93.

    Article  CAS  Google Scholar 

  28. Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C, 191622-096 Investigators. Durable efficacy and safety of long-term OnabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791–800.

    Article  CAS  Google Scholar 

  29. Schurch B, Schmid D, Stohrer M, et al. Treatment of neurogenic incontinence with botulinum toxin. N Engl J Med. 2000;342:665.

    Article  CAS  Google Scholar 

  30. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.

    Article  CAS  Google Scholar 

  31. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003a;61:165–71.

    Article  CAS  Google Scholar 

  32. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, Somogyi GT. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003b;169(5):1896–900.

    Article  CAS  Google Scholar 

  33. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5.

    Article  Google Scholar 

  34. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int. 2005 Sep;47(4):291–7.

    Article  CAS  Google Scholar 

  35. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

    Christopher P. Smith

  2. Aikens Center for Neurourology Research, Department of Urology, Beaumont Health System and Oakland University William Beaumont School of Medicine, Rochester Hills, MI, USA

    Michael B. Chancellor

Authors
  1. Christopher P. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael B. Chancellor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher P. Smith .

Editor information

Editors and Affiliations

  1. Professor Emeritus of Neurology, Yale University School of Medicine, New Haven, CT, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Smith, C.P., Chancellor, M.B. (2020). Botulinum Toxin Treatment in Urological Disorders. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-50691-9_15

Download citation

Publish with us

Policies and ethics

Search

Navigation